Shrimp Hemocyanin elicits a potent humoral response in mammals and is favorable to hapten conjugation

Huiwen Sun,Moris Wei,Amber Guo,Ci Zhang,Yuefeng Wang,Renhui Huang,Xiaoxiao Li,Jeffrey Zhan,Jonny Wu,Bruce Jiang
DOI: https://doi.org/10.1101/2024.01.11.575311
2024-01-15
Abstract:Conjugation to a carrier protein is essential to give rise to the antigenicity of hapten, which is a small molecule and cannot induce an immune response by itself alone. Three carrier proteins e.g. KLH (Keyhole Limpet Hemocyanin), BSA (Bovine Serum Albumin), and OVA (Ovalbumin) were used mostly. KLH is advantageous to the others, majorly owing to its strong immunogenicity and limited usage in other biological assays. However, the solubility of KLH is not as well as the others, especially after hapten conjugation. Besides, the high market price of KLH results in high costs in vaccine and antibody development. Here, we extracted the shrimp hemocyanin (SHC) from with a production yield of > 1 g proteins (98 % pure) per 1 kg shrimp. Compared to KLH, the peptide-SHC conjugates exhibit higher solubility after hapten conjugation. Furthermore, compared with KLH, SHC induces comparable antibody production efficiency in mammals, with or without conjugation. Finally, rabbit polyclonal antibodies or mouse monoclonal antibodies were generated by immunizing SHC-peptide conjugates, and their applications in western blot, immunofluorescence and immunohistochemistry were confirmed. Therefore, we demonstrated that SHC may be used as a substitute for KLH in future antibody and vaccine development.
Bioengineering
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to find a more effective and economical carrier protein for the coupling of hapten and protein, in order to improve the efficiency of antibody and vaccine development. Specifically, the researchers aimed to evaluate whether Shrimp Hemocyanin (SHC) extracted from white - legged shrimp (*Penaeus vannamei*) can replace the commonly - used Keyhole Limpet Hemocyanin (KLH) as a carrier protein. ### Research Background and Problems 1. **Immunogenicity Problems of Hapten**: - Hapten itself is a low - molecular - weight substance and cannot induce an immune response alone. - In order to make it immunogenic, it must be coupled with a carrier protein so that the complex can be processed by antigen - presenting cells and activate the immune system. 2. **Limitations of Existing Carrier Proteins**: - Commonly - used carrier proteins such as KLH, BSA (Bovine Serum Albumin) and OVA (Ovalbumin) have their own advantages and disadvantages. - Although KLH has strong immunogenicity, its solubility is poor, especially after coupling with hapten, which leads to difficulties in downstream purification. In addition, the high price of KLH increases the cost of antibody and vaccine development. 3. **The Need to Find an Alternative Carrier Protein**: - It is necessary to find an alternative with good biochemical characteristics (such as high solubility) and lower economic cost to improve the hapten - carrier protein coupling technology. ### Research Objectives - **Evaluate the Characteristics of SHC**: Verify the solubility and immunogenicity of SHC after coupling with hapten through experiments, as well as its application potential in antibody and vaccine development. - **Compare SHC and KLH**: Compare SHC with KLH and evaluate its performance in the immune response, including antibody production efficiency and the application effects of polyclonal/monoclonal antibodies. ### Main Findings - **High Solubility of SHC**: SHC shows higher solubility than KLH after coupling with hapten, which helps to simplify the subsequent purification steps. - **Strong Immunogenicity of SHC**: The antibody production induced by SHC in mammals is comparable to that of KLH, indicating that it has similar immunogenicity. - **Application Potential of SHC**: Polyclonal and monoclonal antibodies against multiple genes were successfully prepared by immunizing rabbits and mice, and were verified in experiments such as Western blot, immunofluorescence and immunohistochemistry. ### Conclusion This study shows that SHC, as a new - type carrier protein, has the potential to replace KLH in antibody and vaccine development, especially showing significant advantages in improving solubility and reducing cost. Future research will further explore the application prospects of SHC in human vaccine development, while considering possible problems such as allergic reactions. --- I hope the above summary can help you understand the core problems and research contents of this paper. If you have more specific questions or need further information, please feel free to let me know!